Wellington Management Group LLP Has $26.24 Million Holdings in Integra LifeSciences Holdings Corporation $IART

Wellington Management Group LLP boosted its position in shares of Integra LifeSciences Holdings Corporation (NASDAQ:IART) by 12.4% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,461,104 shares of the life sciences company’s stock after purchasing an additional 160,814 shares during the period. Wellington Management Group LLP owned about 1.88% of Integra LifeSciences worth $26,241,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Osaic Holdings Inc. boosted its position in shares of Integra LifeSciences by 36.6% during the second quarter. Osaic Holdings Inc. now owns 4,119 shares of the life sciences company’s stock worth $51,000 after buying an additional 1,104 shares during the period. State of Tennessee Department of Treasury lifted its stake in Integra LifeSciences by 7.9% in the 4th quarter. State of Tennessee Department of Treasury now owns 26,745 shares of the life sciences company’s stock valued at $332,000 after acquiring an additional 1,964 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in Integra LifeSciences by 5.1% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 40,441 shares of the life sciences company’s stock valued at $889,000 after acquiring an additional 1,975 shares in the last quarter. Capital Fund Management S.A. boosted its position in Integra LifeSciences by 5.7% during the 3rd quarter. Capital Fund Management S.A. now owns 37,322 shares of the life sciences company’s stock worth $535,000 after acquiring an additional 1,997 shares during the last quarter. Finally, Global Retirement Partners LLC acquired a new position in Integra LifeSciences during the 4th quarter worth approximately $25,000. Institutional investors and hedge funds own 84.78% of the company’s stock.

Wall Street Analysts Forecast Growth

IART has been the topic of a number of recent research reports. UBS Group initiated coverage on shares of Integra LifeSciences in a report on Tuesday, July 28th. They issued a “neutral” rating and a $19.00 price objective on the stock. Wells Fargo & Company boosted their price target on shares of Integra LifeSciences from $15.00 to $18.00 and gave the stock an “equal weight” rating in a research report on Thursday, July 30th. Truist Financial increased their price objective on shares of Integra LifeSciences from $14.00 to $19.00 and gave the stock a “hold” rating in a research note on Thursday, July 16th. Argus raised Integra LifeSciences from a “hold” rating to a “buy” rating and set a $25.00 target price on the stock in a research report on Thursday, June 18th. Finally, Weiss Ratings upgraded Integra LifeSciences from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, August 14th. One investment analyst has rated the stock with a Buy rating, five have assigned a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Reduce” and a consensus target price of $18.86.

Integra LifeSciences Price Performance

Shares of IART opened at $16.72 on Friday. The company has a current ratio of 3.60, a quick ratio of 2.11 and a debt-to-equity ratio of 1.75. The company’s fifty day simple moving average is $17.80 and its 200 day simple moving average is $14.45. Integra LifeSciences Holdings Corporation has a 1-year low of $8.70 and a 1-year high of $20.49. The company has a market cap of $1.30 billion, a price-to-earnings ratio of -185.76, a PEG ratio of 0.86 and a beta of 1.21.

Integra LifeSciences (NASDAQ:IART) last announced its quarterly earnings results on Wednesday, July 29th. The life sciences company reported $0.56 EPS for the quarter, beating analysts’ consensus estimates of $0.48 by $0.08. Integra LifeSciences had a negative net margin of 0.44% and a positive return on equity of 18.30%. The firm had revenue of $418.76 million during the quarter, compared to analysts’ expectations of $417.54 million. Integra LifeSciences has set its Q3 2026 guidance at 0.530-0.610 EPS and its FY 2026 guidance at 2.400-2.500 EPS. On average, research analysts forecast that Integra LifeSciences Holdings Corporation will post 2.46 earnings per share for the current fiscal year.

About Integra LifeSciences

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.